These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37432070)

  • 1. Quantitative Evaluation of Progression of Retinal Vascularization After 60 Weeks Postmenstrual Age in Infants Treated With Bevacizumab.
    Bayramoğlu SE; Sayin N
    Ophthalmic Surg Lasers Imaging Retina; 2023 Jul; 54(7):417-424. PubMed ID: 37432070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Intravitreal Bevacizumab Dose on Retinal Vascular Progression in Retinopathy of Prematurity.
    Bayramoglu SE; Sayin N
    Ophthalmologica; 2022; 245(2):161-172. PubMed ID: 34844257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment.
    Bayramoglu SE; Sayin N
    Eur J Ophthalmol; 2022 May; 32(3):1430-1440. PubMed ID: 34851169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
    Mintz-Hittner HA; Geloneck MM; Chuang AZ
    Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescein Angiography Findings in Treatment-Naive Premature Infants with Retinal Vascular Immaturity and Persistent Avascular Retina.
    Bayramoglu SE; Sayın N
    Semin Ophthalmol; 2022 Aug; 37(6):740-748. PubMed ID: 35671203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.
    Wu L; Li M; Wang L; Yan H; Zhou Z; Fan J; Zhou Y; Gou K; Guo C; Wang Y; Zhang Z
    Sci Rep; 2023 Nov; 13(1):19946. PubMed ID: 37968276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab.
    Bayramoglu SE; Sayin N
    Indian J Ophthalmol; 2022 Oct; 70(10):3584-3590. PubMed ID: 36190051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years.
    Hammer JD; Nguyen H; Palmer J; Furtney S; Agarwal-Sinha S
    Clin Ther; 2023 Jan; 45(1):4-16. PubMed ID: 36581528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
    Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
    Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
    Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
    Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina.
    Gonzalez A; Agarwal-Sinha S
    Can J Ophthalmol; 2020 Oct; 55(5):373-381. PubMed ID: 32835673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Findings in Persistent Retinopathy of Prematurity.
    Warren CC; Young JB; Goldberg MR; Connor TB; Kassem IS; Costakos DM
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):497-503. PubMed ID: 30021036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab.
    Alyamaç Sukgen E; Çömez A; Koçluk Y; Cevher S
    Ophthalmologica; 2016; 236(3):139-147. PubMed ID: 27682852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.
    Sternfeld A; Rahmani S; Rossen JL; Zhang DL; Li YD; Quan VL; Huang R; Yoon HH
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1915-1921. PubMed ID: 34851464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.
    Padhi TR; Das T; Rath S; Pradhan L; Sutar S; Panda KG; Modi R; Jalali S
    Eye (Lond); 2016 Mar; 30(3):392-9. PubMed ID: 26584796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study.
    Lorenz B; Stieger K; Jäger M; Mais C; Stieger S; Andrassi-Darida M
    Retina; 2017 Jan; 37(1):97-111. PubMed ID: 27454223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.
    Mansukhani SA; Hutchinson AK; Neustein R; Schertzer J; Allen JC; Hubbard GB
    Ophthalmol Retina; 2019 May; 3(5):436-443. PubMed ID: 31044736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
    Bayramoglu SE; Sayin N
    Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.